Omnimmune Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMMH research report →
About the company
Omnimmune Holdings, Inc. , through its subsidiary, Omnimmune Corp. , operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States.
- CEO
- Saul Leal
- IPO
- 2007
- Employees
- 2
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $981
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 38.41%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,761,268 · 70.60%
- EPS
- $-0.20 · 80.00%
- Op Income
- $-1,522,060
- FCF YoY
- 86.79%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.07
- Avg Volume
- 95.83K
Get TickerSpark's AI analysis on OMMH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our OMMH coverage
Recent articles, reports, and earnings notes.
No research on OMMH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OMMH report →Similar companies
Peers in the same neighborhood.